Mixed Dementias

Dementias caused by multiple etiologies, e.g., ALZHEIMER DISEASE, and VASCULAR DEMENTIA and/or LEWY BODY DISEASE.

Also Known As:

Dementia, Mixed; Dementia, Mixed-Etiology; Dementia, Multiple-Etiology; Mixed Dementia; Mixed Etiology Dementias; Mixed-Etiology Dementia; Multiple Etiology Dementias; Multiple-Etiology Dementia; Mixed-Etiology Dementias; Multiple-Etiology Dementias

Networked: 183 relevant articles (17 outcomes, 38 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease)
2.	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy)
3.	Cognitive Dysfunction
4.	Dementia (Dementias)
5.	Lewy Body Disease (Lewy Body Dementia)

Experts

1.	Santamaría, Enrique: 5 articles (10/2021 - 11/2015)
2.	Sherriff, F: 5 articles (07/2005 - 01/2003)
3.	Eriksdotter, Maria: 4 articles (01/2022 - 01/2014)
4.	Fernández-Irigoyen, Joaquín: 4 articles (10/2021 - 01/2017)
5.	Kim, Hee Jin: 4 articles (12/2018 - 01/2013)
6.	Na, Duk L: 4 articles (12/2018 - 01/2013)
7.	Seo, Sang Won: 4 articles (12/2018 - 01/2013)
8.	McShane, R: 4 articles (04/2006 - 10/2004)
9.	Areosa, Sastre A: 4 articles (07/2005 - 01/2003)
10.	Herrmann, Nathan: 3 articles (01/2022 - 01/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Mixed Dementias:

1.	Rivastigmine (Exelon)FDA LinkGeneric 01/01/2006 - "The object of this study was to assess the efficacy and safety of rivastigmine in patients with mixed dementia (AD with VaD). " 01/01/2006 - "This pilot study suggests that rivastigmine treatment may have beneficial effects in the treatment of patients with mixed dementia." 01/01/2006 - "A pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia." 01/01/2003 - "Preliminary data suggest that rivastigmine may provide significant benefits in patients with AD and cerebrovascular disease (mixed dementia), and in patients with VaD. " 05/31/2013 - "All unconfounded randomized double-blind trials comparing rivastigmine with placebo in the treatment of people with VCI, vascular dementia or mixed dementia were eligible for inclusion. "
2.	Cholinesterase Inhibitors (Anticholinesterases)IBA 06/01/2013 - "Cholinesterase inhibitors modulate autonomic function in patients with Alzheimer´s disease and mixed dementia." 01/01/2013 - "[Cholinesterase inhibitors in the treatment of mixed dementia]." 01/01/2003 - "The treatment of vascular or mixed dementia involves control of the risk factors for continued vascular events and treatment with the cholinesterase inhibitors." 12/15/2004 - "Cholinesterase inhibitor (ChI) therapy for mixed dementia shows modest clinical benefits that are similar to those found for ChI treatment of AD. " 01/01/2017 - "No drugs are clearly effective in vascular dementia, though cholinesterase inhibitors are beneficial in mixed dementia (B). "
3.	Galantamine (Galanthamine)FDA LinkGeneric 08/01/2022 - "Association study identifies genetic determinants and non-genetic factors on steady-state plasma and therapeutic outcome of galantamine in mixed dementia." 08/01/2022 - "Fifty-one Thai patients with mixed dementia who received galantamine for at least 6 months were recruited. " 10/01/2002 - "Galantamine has also shown efficacy in mixed dementia. " 11/15/2016 - "A large, prospective, 2-year, randomized study in patients with mild-to-moderate Alzheimer's disease or mixed dementia demonstrated reductions in mortality and cognitive/functional decline in galantamine-treated patients. " 06/01/2003 - "An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia."
4.	Nafronyl (Naftidrofuryl)IBA 07/01/2000 - "This study examined the efficacy of naftidrofuryl in patients with vascular or mixed dementia. " 07/01/2000 - "Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results of a multicenter, double-blind trial." 10/01/2000 - "The efficacy of naftidrofuryl in patients with vascular or mixed dementia." 07/01/2000 - "The results of this study suggest that naftidrofuryl is effective and well tolerated in treating the symptoms of vascular and mixed dementia." 07/01/2000 - "This multicenter, randomized, double-blind study compared naftidrofuryl 600 mg/d with placebo for 1 year in patients with vascular or mixed dementia. "
5.	Cholinergic Agents (Cholinergics)IBA 01/01/2003 - "Cholinergic therapies have proven efficacious in the treatment of Alzheimer's disease, and recently in vascular and mixed dementia. " 01/01/2003 - "Previous results from a 6-month, double-blind, placebo-controlled, international, multicentre study of the cholinomimetic galantamine in patients with probable vascular dementia or mixed dementia (Alzheimer's disease with cerebrovascular disease) showed significant cognitive, behavioural and functional benefits in these patients. " 05/10/2003 - "In cases of dementia with cholinergic deficiency (Alzheimer, Lewy body dementia, mixed dementia) cholinesterase inhibitors have demonstrated their efficacy on the hallucinations. " 12/01/2016 - "Acetylcholinesterase inhibitors (AchEIs), such as rivastigmine, coadministered with cholinergic precursors, such as citicoline, could be effective in Alzheimer's disease (AD) and in mixed dementia (MD), because they are able to increase the intrasynaptic levels of acetylcholine more than the single drugs given alone. "
6.	Cytidine Diphosphate Choline (Citicoline)IBA 01/01/2022 - "The present article reports an overview of the studies about combination treatment with citicoline of Alzheimer's (AD) and mixed dementia (MD). " 01/01/2022 - "A Medline search was carried out by using the keywords Alzheimer's dementia, mixed dementia, older people, treatment with citicoline, memantine, and acetylcholinesterase inhibitors (AchEIs). " 12/01/2016 - "Acetylcholinesterase inhibitors (AchEIs), such as rivastigmine, coadministered with cholinergic precursors, such as citicoline, could be effective in Alzheimer's disease (AD) and in mixed dementia (MD), because they are able to increase the intrasynaptic levels of acetylcholine more than the single drugs given alone. "
7.	ActoveginIBA 11/15/2012 - "These data, coupled with positive results from clinical trials in mixed dementia populations, have served as a foundation for the design of a new trial investigating the efficacy and disease-modifying effects of Actovegin in post-stroke cognitive impairment."
8.	Amyloid (Amyloid Fibrils)IBA 12/01/2018 - "Five patients underwent amyloid PET: two with AD, one with mixed dementia, one with FTD, and one with CJD. " 10/12/2015 - "As such, therapeutic approaches targeting SVCI must consider the potential role of amyloid for the optimal care of those with mixed dementia. " 02/01/2014 - "The concept of mixed dementia has emerged to more clearly identify patients with neurodegenerative phenomena exhibiting both AD and cerebral vascular pathologies-vascular damage along with β-amyloid (Aβ)-associated neurotoxicity and τ-hyperphosphorylation. " 01/01/2013 - "Identifying mixed dementia from SVaD is important because potential amyloid-targeted therapies may be effective for treatment in mixed dementia. " 01/01/2018 - "Alzheimer's associated amyloid and tau deposition co-localizes with a homeostatic myelin repair pathway in two mouse models of post-stroke mixed dementia."
9.	Antidepressive Agents (Antidepressants)IBA 01/01/2016 - "Antidepressant prescriptions in individuals with AD, mixed dementia (MD), and vascular dementia (VaD) in the French National Alzheimer Database between 2010 and 2014 were analyzed (N = 199,544). " 02/16/2011 - "To assess the safety and efficacy of antidepressants in treating psychosis and agitation in older adults with Alzheimer's disease, vascular, or mixed dementia. "
10.	Acetylcholine (Acetylcholine Chloride)FDA Link 12/01/2016 - "Acetylcholinesterase inhibitors (AchEIs), such as rivastigmine, coadministered with cholinergic precursors, such as citicoline, could be effective in Alzheimer's disease (AD) and in mixed dementia (MD), because they are able to increase the intrasynaptic levels of acetylcholine more than the single drugs given alone. "

Therapies and Procedures

1.	Therapeutics 01/01/2021 - "We report a case of a patient with mixed dementia successfully treated with a personalized multimodal therapy. " 01/01/2019 - "This novel rat model of MxD, encompassing an amyloidogenic transgene with a hypertensive phenotype, exhibits several features associated with human vascular or "mixed" dementia and may be a useful tool in delineating the pathophysiology of MxD and development of therapeutics." 06/01/2013 - "Thirty-nine patients with Alzheimer´s disease or mixed dementia underwent a comprehensive clinical evaluation, prior to and during ChEIs therapy, including orthostatic challenge, electrocardiogram (EKG) and heart rate variability (HRV) spectral analysis through Holter recordings. " 12/15/2004 - "To provide an overview of the diagnosis, pathophysiology, and interaction of AD and VaD in mixed dementia, and to provide a systematic literature review of the current evidence for the pharmacologic therapy of mixed dementia. " 01/01/2020 - "This suggests that many individuals diagnosed with Alzheimer's disease may actually suffer from a mixed dementia, and therapeutics targeting only Alzheimer's disease-related processes may have severely limited efficacy in these co-morbid populations."
2.	Cognitive Training 05/27/2013 - "Preliminary evidence suggests that goal-oriented cognitive rehabilitation (CR) may be a clinically effective intervention for people with early-stage Alzheimer's disease, vascular or mixed dementia and their carers. " 01/01/2017 - "It was stated that dosed walking with cognitive training interventions improved cognitive performance in patients with probable Alzheimer's disease to a greater extent as compared to a single medical therapy and patients with mixed dementia probably due to severe structural changes of the brain. " 01/01/2017 - "The dosed walking efficacy with including the cognitive training as the component of complex therapy of mild and moderate dementia was examined in elderly patients with the probable Alzheimer's disease and mixed dementia. "
3.	Home Nursing (Nursing, Home) 01/01/2017 - "The aims of this study are to (1) explore the determinants of quality of life (QoL) in nursing home residents with young-onset dementia (YOD), (2) investigate whether there are differences between dementia subtypes (Alzheimer dementia, vascular/mixed dementia, frontotemporal dementia, other) regarding these determinants, and (3) compare QoL profiles of YOD nursing home residents across dementia subtypes. " 08/22/2023 - "A Tablet-Based App to Support Nursing Home Staff in Delivering an Individualized Cognitive and Physical Exercise Program for Individuals With Dementia: Mixed Methods Usability Study." 12/01/2005 - "To evaluate the efficacy and safety of low-dose risperidone in treating psychosis of Alzheimer's disease (AD) and mixed dementia (MD) in a subset of nursing-home residents who had dementia and aggression and who were participating in a randomized placebo-controlled trial of risperidone for aggression. "
4.	Long-Term Care 01/01/2022 - "To characterize BPSD in Alzheimer's disease (AD), vascular dementia (VaD), mixed (Mixed) dementia, Parkinson's disease dementia (PDD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), and unspecified dementia in individuals residing in long-term care facilities. " 11/11/2020 - "We employed clinical data from 717 people from 3 sources: (1) a memory clinic; (2) long-term care; and (3) an open-label trial of donepezil in vascular and mixed dementia (VASPECT). " 01/01/2009 - "A total of 10 mg or 15 mg of IM aripiprazole administered in divided doses was safe and well tolerated for treatment of agitation associated with Alzheimer's, vascular, or mixed dementia in long-term care. "
5.	Activities of Daily Living (ADL) 01/01/2017 - "This study indicates that high AGE levels could be a contributing factor to impaired mobility but lacks evidence for an association with ADL decline in people with early stage AD or mixed dementia. " 01/01/2017 - "A total of 160 carers returned the Interview for Deteriorations in Daily Living Activities in Dementia 2, of which 109, 21, and 30 cared for someone with AD, VaD, and mixed dementia, respectively. "